CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
Abstract Background Mesothelioma is an incurable, apoptosis-resistant cancer caused in most cases by previous exposure to asbestos and is increasing in incidence. It represents a growing health burden but remains under-researched, with limited treatment options. Early promising signals of activity r...
Main Authors: | Dean A. Fennell, Emma Kirkpatrick, Kelly Cozens, Mavis Nye, Jason Lester, Gerard Hanna, Nicola Steele, Peter Szlosarek, Sarah Danson, Joanne Lord, Christian Ottensmeier, Daniel Barnes, Stephanie Hill, Mihalis Kalevras, Tom Maishman, Gareth Griffiths |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | Trials |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13063-018-2602-y |
Similar Items
-
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
by: Kazuya Tsubouchi, et al.
Published: (2020-04-01) -
Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor
by: Kimihiro Shimatani, et al.
Published: (2018-03-01) -
Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab
by: Li Li, et al.
Published: (2017-03-01) -
First-line treatment of metastatic melanoma: role of nivolumab
by: Force J, et al.
Published: (2017-02-01) -
Evidence from a meta-analysis: is nivolumab neurotoxic in cancer patients?
by: Kong X, et al.
Published: (2017-03-01)